Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 28;13:1211759. doi: 10.3389/fonc.2023.1211759

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Liang, Zheng, Liu, Mei, Zhou, Xiao, Qin, Yue, Lin, Liu, Li and Yu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

BAT6026 treatment decreased Tregs proportion, increased CD8+ T cell proportion and activated both CD4+ and CD8+ T cells in tumor. OX40-humanized mice bearing MC38 tumor were dosed with 5 mg/kg BAT6026-mIgG2a or BAT6026-mIgG2a-wt on days 9 and 14 post tumor injection. Single cell suspensions from tumors and spleens were collected and analyzed by flow cytometry 48 hrs after the last dose. (A) The percentage of CD4+ T cells, Treg and CD8+ T cells in tumor. (B) The percentage of CD4+ T cells, Treg and CD8+ T cells in spleen. (C) The percentage of IFN-γ+ or Ki67+ CD4+ and IFN-γ+ or Ki67+ CD8+ T in tumor. (D) The percentage of IFN-γ+ or Ki67+ CD4+ and IFN-γ+ or Ki67+ CD8+ T cells in spleen. Data shown as mean ± SEM, N=6. Ordinary one-way ANOVA was used (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, no significant difference).